» Articles » PMID: 10070877

Induction of MDR1 Gene Expression by Anthracycline Analogues in a Human Drug Resistant Leukaemia Cell Line

Overview
Journal Br J Cancer
Specialty Oncology
Date 1999 Mar 10
PMID 10070877
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50 and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 microM) and PSC 833 (1 microM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period.

Citing Articles

Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T Am J Cancer Res. 2015; 5(8):2431-40.

PMID: 26396918 PMC: 4568778.


Cyclosporine A enables vincristine-induced apoptosis during reversal of multidrug resistance phenotype in chronic myeloid leukemia cells.

de Souza P, da Cunha Vasconcelos F, Silva L, Maia R Tumour Biol. 2012; 33(4):943-56.

PMID: 22290425 DOI: 10.1007/s13277-012-0323-5.


Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells.

Gouaze-Andersson V, Yu J, Kreitenberg A, Bielawska A, Giuliano A, Cabot M Biochim Biophys Acta. 2007; 1771(12):1407-17.

PMID: 18035065 PMC: 3569095. DOI: 10.1016/j.bbalip.2007.09.005.


Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.

Hu X, Li J, Yang E, Vandervalk S, Xing P Br J Cancer. 2007; 96(6):918-27.

PMID: 17342096 PMC: 2360102. DOI: 10.1038/sj.bjc.6603641.

References
1.
Shustik C, Dalton W, Gros P . P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med. 1995; 16(1):1-78. DOI: 10.1016/0098-2997(94)00040-a. View

2.
Hu X, Slater A, Wall D, Parkin J, Kantharidis P, Zalcberg J . Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res. 1996; 2(4):713-20. View

3.
Rohlff C, Glazer R . Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal. 1995; 7(5):431-43. DOI: 10.1016/0898-6568(95)00018-k. View

4.
Beketic-Oreskovic L, Duran G, Chen K, Dumontet C, Sikic B . Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst. 1995; 87(21):1593-602. DOI: 10.1093/jnci/87.21.1593. View

5.
Ross D, Doyle L, Yang W, Tong Y, Cornblatt B . Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol. 1995; 50(10):1673-83. DOI: 10.1016/0006-2952(95)02069-1. View